The role of high-dose therapy and autologous stem cell transplantation in patients with primary refractory Hodgkin's lymphoma: A report from the Gruppo Italiano per lo Studio dei Linfomi (GISL)

Bone Marrow Transplantation

Volumn 37, Issue 3, 2006, Pages 283-288

  Morabito, Fortunato ^a   Stelitano, C ^b   Luminari, S ^c   Mammi, C ^c   Marcheselli, L ^c   Callea, V ^b   Gentile, M ^a   Polimeno, G ^d   Merli, F ^e   Molica, S ^f   Gobbi, P ^g   Angrilli, F ^h   Brugiatelli, M ⁱ   Federico, M ^c  

^a Azienda Ospedaliera di Cosenza   (Italy)

^b BIANCHI MELACRINO MORELLI HOSPITAL   (Italy)

^c UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^d MIULLI GENERAL HOSPITAL   (Italy)

^e S MARIA NUOVA HOSPITAL   (Italy)

^f PUGLIESE CIACCIO HOSPITAL   (Italy)

^g UNIVERSITY OF PAVIA   (Italy)

^h SPIRITO SANTO HOSPITAL   (Italy)

ⁱ Azienda Ospedaliera Papardo   (Italy)

Author keywords

Autologous bone marrow transplantation; Conventional chemotherapy; Overall survival; Refractory Hodgkin's lymphoma

Indexed keywords

BLEOMYCIN; CHLORMETHINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; LOMUSTINE; MELPHALAN; METHOTREXATE; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE; VINDESINE;

ADOLESCENT; ADULT; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER MORTALITY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HODGKIN DISEASE; HUMAN; ITALY; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; SALVAGE THERAPY; SCORING SYSTEM; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; TREATMENT FAILURE; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; DATA COLLECTION; FEMALE; HODGKIN DISEASE; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SALVAGE THERAPY; STEM CELL TRANSPLANTATION; SURVIVAL RATE; TRANSPLANTATION, AUTOLOGOUS;

EID: 33645283388     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/sj.bmt.1705235     Document Type: Article

References (34)

1. Diehl V, Thomas RK, Re D. Part II: Hodgkin's lymphoma - diagnosis and treatment. Lancet Oncol 2004; 5: 19-26.
2. Diehl V, Stein H, Hummel M, Zollinger R, Connors JM. Hodgkin's lymphoma: biology and treatment strategies for primary, refractory, and relapsed disease. Hematology (Am Soc Hematol Educ Program) 2003, 225-247.
3. Yung L, Linch D. Hodgkin's lymphoma. Lancet 2003; 361: 943-951.
4. Aisenberg AC. Problems in Hodgkin's disease management. Blood 1999; 93: 761-779.
5. Aparicio J, Segura A, Garcera S, Oltra A, Santaballa A, Yuste A et al. ESHAP is an active regimen for relapsing Hodgkin's disease. Ann Oncol 1999; 10: 593-595.
6. Josting A, Rudolph C, Reiser M, Mapara M, Sieber M, Kirchner HH et al. Time-intensified dexamethasone/cisplatin/cytarabine: An effective salvage therapy with low toxicity in patients with relapsed and refractory Hodgkin's disease. Ann Oncol 2002; 13: 1628-1635.
7. Schmitz N, Pfistner B, Sextro M, Sieber M, Carella AM, Haenel M et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: A randomised trial. Lancet 2002; 359: 2065-2071.
8. Magagnoli M, Sarina B, Balzarotti M, Castagna L, Timofeeva I, Nozza A et al. Mobilizing potential of ifosfamide/vinorelbine-based chemotherapy in pretreated malignant lymphoma. Bone Marrow Transplant 2001; 28: 923-927.
9. Gobbi PG, Broglia C, Merli F, Dell'Olio M, Stelitano C, Iannitto E et al. Vinblastine, bleomycin, and methotrexate chemotherapy plus irradiation for patients with early-stage, favorable Hodgkin lymphoma: the experience of the Gruppo Italiano Studio Linfomi. Cancer 2003; 98: 2393-2401.
10. Bonadonna G, Zucali R, Monfardini S, De Lena M, Uslenghi C. Combination chemotherapy of Hodgkin's disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP. Cancer 1975; 36: 252-259.
11. Canellos GP, Gollub J, Neuberg D, Mauch P, Shulman LN. Primary systemic treatment of advanced Hodgkin's disease with EVA (etoposide, vinblastine, doxorubicin): 10-year follow-up. Ann Oncol 2003; 14: 268-272.
12. Gobbi PG, Pieresca C, Ghirardelli ML, Di Renzo N, Federico M, Merli F et al. Long-term results from MOPPEBVCAD chemotherapy with optional limited radiotherapy in advanced Hodgkin's disease. Blood 1998; 91: 2704-2712.
13. Diehl V, Franklin J, Pfreundschuh M, Lathan B, Paulus U, Hasenclever D et al. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med 2003; 348: 2386-2395.
14. Horning S, Rosenberg S, Hoppe R. Brief chemotherapy (Stanford V) and adjuvant radiotherapy for bulky or advanced Hodgkin's disease: An update. Ann Oncol 1996; 7 (Suppl 4): 105-108.
15. DeVita Jr VT, Simon RM, Hubbard SM, Young RC, Berard CW, Moxley JH et al. Curability of advanced Hodgkin's disease with chemotherapy long-term follow-up of MOPP-treated patients at the National Cancer Institute. Ann Intern Med 1980; 92: 587-595.
16. Longo DL, Duffey PL, Young RC, Hubbard SM, Ihde DC, Glatstein E et al. Conventional dose salvage combination chemotherapy in patients relapsing with Hodgkin's disease after combination chemotherapy: The low probability for cure. J Clin Oncol 1992; 10: 210-218.
17. Bonfante V, Santoro A, Viviani S, Devizzi L, Balzarotti M, Soncini F et al. Outcome of patients with Hodgkin's disease failing after primary MOPP-ABVD. J Clin Oncol 1997; 15: 528-534.
18. Josting A, Rueffer U, Franklin J, Sieber M, Diehl V, Engert A. Prognostic factors and treatment outcome in primary progressive Hodgkin lymphoma: A report from the German Hodgkin Lymphoma Study Group. Blood 2000; 96: 1280-1286.
19. Ferme C, Mounier N, Divine M, Brice P, Stamatoullas A, Reman O et al. Intensive salvage therapy with high-dose chemotherapy for patients with advanced Hodgkin's disease in relapse or failure after initial chemotherapy: Results of the Groupe d'Etudes des Lymphomes de l'Adulte H 89 Trial. J Clin Oncol 2002; 20: 467-475.
20. Czyz J, Hellmann A, Dziadziuszko R, Hansz J, Gozdzik J, Holowiecki J et al. High-dose chemotherapy with autologous stem cell transplantation is an effective treatment of primary refractory Hodgkin's disease. Retrospective study of the Polish Lymphoma Research Group. Bone Marrow Transplant 2002; 30: 29-34.
21. Czyz J, Szydlo R, Knopinska-Posluszny W, Hellmann A, Gozdzik J, Hansz J et al. Treatment for primary refractory Hodgkin's disease: A comparison of high-dose chemotherapy followed by ASCT with conventional therapy. Bone Marrow Transplant 2004; 33: 1225-1229.
22. Constans M, Sureda A, Terol MJ, Arranz R, Caballero MD, Iriondo A et al. Autologous stem cell transplantation for primary refractory Hodgkin's disease: Results and clinical variables affecting outcome. Ann Oncol 2003; 14: 745-751.
23. Sweetenham JW, Carella AM, Taghipour G, Cunningham D, Marcus R, Della Volpe A et al. High-dose therapy and autologous stem-cell transplantation for adult patients with Hodgkin's disease who do not enter remission after induction chemotherapy: Results in 175 patients reported to the European Group for Blood and Marrow Transplantation. Lymphoma Working Party. J Clin Oncol 1999; 17: 3101-3109.
24. André M, Henry-Amar M, Pico JL, Brice P, Blaise D, Kuentz M et al. Comparison of high-dose therapy and autologous stem-cell transplantation with conventional therapy for Hodgkin's disease induction failure: A case-control study. Societé Francaise de Greffe de Moelle. J Clin Oncol 1999; 17: 222-229.
25. Zinzani PL, Tani M, Gabriele A, Gherlinzoni F, de Vivo A, Ricci P et al. High-dose therapy with autologous transplantation for Hodgkin's disease: the Bologna experience. Haematologica 2003; 88: 522-528.
26. Tarella C, Cuttica A, Vitolo U, Liberati M, Di Nicola M, Cortelazzo S et al. High-dose sequential chemotherapy and peripheral blood progenitor cell autografting in patients with refractory and/or recurrent Hodgkin lymphoma: A multicenter study of the Intergruppo Italiano Linfomi showing prolonged disease free survival in patients treated at first recurrence. Cancer 2003; 97: 2748-2759.
27. Yahalom J, Gulati SC, Toia M, Maslak P, McCarron EG, O'Brien JP et al. Accelerated hyperfractionated total-lymphoid irradiation, high-dose chemotherapy, and autologous bone marrow transplantation for refractory and relapsing patients with Hodgkin's disease. J Clin Oncol 1993; 11: 1062-1070.
28. Carella AM, Congiu AM, Gaozza E, Mazza P, Ricci P, Visani G et al. High-dose chemotherapy with autologous bone marrow transplantation in 50 advanced resistant Hodgkin's disease patients: An Italian study group report. J Clin Oncol 1988; 6: 1411-1416.
29. Gribben JG, Linch DC, Singer CR, McMillan AK, Jarrett M, Goldstone AH. Successful treatment of refractory Hodgkin's disease by high-dose combination chemotherapy and autologous bone marrow transplantation. Blood 1989; 73: 340-344.
30. Reece DE, Barnett MJ, Connors JM, Fairey RN, Fay JW, Greer JP et al. Intensive chemotherapy with cyclophosphamide, carmustine, etoposide followed by autologous bone marrow transplantation for relapsed Hodgkin's disease. J Clin Oncol 1991; 9: 1871-1879.
31. Lazarus HM, Rowlings PA, Zhang MJ, Vose JM, Armitage JO, Bierman PJ et al. Autotransplant for Hodgkin's disease in patients never achieving remission: A report from the Autologous Blood and Marrow Transplant Registry. J Clin Oncol 1999; 17: 534-545.
32. Kumar R, Maillard I, Schuster SJ, Alavi A. Utility of fluorodeoxyglucose-PET imaging in the management of patients with Hodgkin's and non-Hodgkin's lymphomas. Radiol Clin N Am 2004; 42: 1083-1100.
33. Schmitz N, Sureda A, Robinson S. Allogeneic transplantation of hematopoietic stem cells after nonmyeloablative conditioning for Hodgkin's disease: Indications and results. Semin Oncol 2004; 31: 27-32.
34. Bollard CM, Aguilar L, Straathof KC, Gahn B, Huls MH, Rousseau A et al. Cytotoxic T lymphocyte therapy for Epstein-Barr virus + Hodgkin's disease. J Exp Med 2004; 200: 1623-1633.